



CONSUMER PERCEPTION OF SELF-AID MATERIALS IN OVER-
THE-COUNTER NICOTINE PATCH
Shi CW, Zhu SH, Jain S, Becerra L, Ganiats T
UC San Diego, La Jolla, CA, USA
OBJECTIVES: Over-the-counter (OTC) nicotine patch products
contain self-aid materials as a surrogate for formal physician
counseling. Little is known about whether consumers utilize
these resources and what their perceptions are of these materi-
als. We undertook a study to explore this issue. METHODS:
Adult consumers (N = 155) of OTC nicotine patch from 30 retail
pharmacies in San Diego County were recruited to complete a
self-administered questionnaire two weeks after purchase. The
questionnaire asked participants in an open-ended format
whether they elected to use the enclosed CD-ROM, a self-aid
tool, and the reasons behind their decision. Immersion/crystal-
lization methods were used to extract major themes. Logistic
regression was performed to explore factors associated with CD-
ROM use. RESULTS: Of the 22% percent who used the CD-
ROM, 26% stated that the material was helpful. Among the
78% who did not use the CD-ROM, most believed the material
would not augment their knowledge or motivation for quitting.
Other reasons for not viewing the CD-ROM included having no
time or seen similar materials in the past, lost or cannot ﬁnd the
CD-ROM, and forgetting to use the material. Utilization of CD-
ROM was more likely among individuals who live with multi-
ple smokers, have poor self-rated health status, experience
side-effects with the patch, and believe the patch is inexpensive.
CONCLUSION: Although self-aid materials are included in 
each OTC nicotine patch package, few consumers utilize this
resource. Even among those who did review the material, few
found it helpful. The current material appears to have more
application for those with multiple impeding factors to quitting.
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A RETROSPECTIVE COMPARATIVE ANALYSIS OF TREATMENT
OUTCOMES OF ALPHA-BLOCKERS IN THE MANAGEMENT OF
BENIGN PROSTATIC HYPERPLASIA WITHIN A MANAGED
CARE POPULATION
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OBJECTIVES: Benign prostatic hyperplasia (BPH) is a highly
prevalent condition, affecting more than 50% of men aged >60
years. Alpha1-adrenergic blockers (ABs) tamsulosin, alfuzosin,
doxazosin, and terazosin are commonly used pharmacologic
treatments for benign prostatic hyperplasia (BPH). However,
there are limited data on intra-class comparisons of ABs with
respect to treatment failure, particularly in the U.S. This study
aimed to assess the rate of treatment failure with tamsulosin
versus other ABs among patients with BPH in a U.S. setting.
METHODS: A retrospective database analysis was performed
using health care claims for patients with an ICD-9 diagnosis for
BPH between 1Q2000 and 3Q2005. Only patients, aged >35
years, newly initiated with AB therapy were included; those with
a history of prostate or urogenital disease were excluded. Treat-
ment failure was deﬁned as switching to another AB therapy or
undergoing BPH-related surgery. Time-to-treatment failure was
assessed using Kaplan-Meier survival analyses; Cox proportional
hazard regression models were used to control for differences in
baseline characteristics. Alfuzosin, introduced in 2004, was eval-
uated in an exploratory analysis with a shorter, 15-month
follow-up period. RESULTS: At baseline, patients receiving tam-
sulosin (n = 10,340) were younger and more likely to see urol-
ogists than those receiving doxazosin (n = 3088) or terazosin (n
= 2710) (p < 0.050 for all). Rates of treatment failure were lower
for patients receiving tamsulosin compared to those receiving
doxazosin and terazosin in the Kaplan-Meier analysis (p < 0.001
for both); multivariate Cox regression models conﬁrmed these
ﬁndings versus doxazosin (HR = 1.8, p < 0.001) and terazosin
(HR = 2.1, p < 0.001). Compared to tamsulosin, patients receiv-
ing alfuzosin (n = 608) were also at greater risk of treatment
failure (HR = 2.6, p < 0.001). CONCLUSION: Among the study
population, initial treatment with tamsulosin resulted in reduced
rate of treatment failure compared to doxazosin and terazosin.
Deﬁnitive conclusions for alfuzosin require studies with longer
follow-up periods.
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OUTCOMES AND COSTS ASSOCIATED WITH
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OBJECTIVES: Estimates from transplant centers and clinical
trials indicate approximately 30% of kidney transplant recipi-
ents are poorly compliant to their immunosuppressive (IS)
regimen. This behavior may be the underlying cause of a large
fraction of late acute rejection episodes and graft loss. Here we
examine the survival and economic outcomes associated with
varying degrees of compliance. METHODS: Compliance was
deﬁned as a medication possession ratio (MPR: % days with
medication in a year according to pharmacy claim records sub-
mitted to Medicare) for 12,185 kidney recipients with at least 1
year of function, transplanted from 1998–2002 with data pro-
vided by the United States Renal Data System. Patient cohorts
were deﬁned by MPR quartiles (lowest <72%, median = 89%,
highest >96%). Reported costs are average accumulated
Medicare payments for IS, inpatient and outpatient medical care
after the transplant procedure. RESULTS: As expected, ﬁrst-year
IS costs were lowest for the low quartile ($5.0 K vs. $9.4–12.4
K for the higher quartiles). 3-year graft survival, conditional on
1-year function was 89, 89, 91 and 93% with increasing MPR
for the 4 quartiles (P by log rank <0.001). 20% (n = 1636) of
patients remained in the two lower quartiles and 7% (n = 532)
in the highest quartile for all three years of the study. Cost curves
indicate that although 3-year IS costs were $16.1 K higher for
patients persisting in the high quartile($32.0 vs $15.8 k), medical
costs were $27.2 K less than the lower MPR cohort patients
($31.8 vs 58.9 K). Logistic regression propensity analysis com-
paring the two cohorts indicate patients under age 25 (relative
risk = 1.60, 95% conﬁdence interval 1.01–2.52, P = 0.05), and
African Americans (1.74, 1.36–2.22, P < 0.001) were more likely
in the low MPR cohort. CONCLUSION: Examination of
Medicare claims indicates patients with persistent high IS com-
pliance, incurred 15% lower overall 3-year costs ($11.1 K) com-
pared to those persistently low. These results indicate excellent
immunosuppression compliance should be encouraged.
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OBJECTIVES: To determine a proﬁle of renal transplant recip-
ients (RTRs) who are at highest risk for immunosuppressant
therapy (IST) non-adherence. METHODS: Retrospective analy-
sis was performed on follow-up non-adherence data routinely
reported by transplant centers to the United Network for Organs
Sharing in the United States Renal Data System. Those who
received transplants on or after January 1, 1995, had at least 36
months of follow-up data, and did not receive a second renal
transplant were included in the analyses. Random effects logit
regression was used to estimate risk of non-adherence while con-
trolling for age, race, education, donor type, primary insurance
and IST including cyclosporine (CSA), tacrolimus (TAC), aza-
thioprine (AZA), mycophenolate mofetil (MMF) and steroids.
Association between IST non-adherence and graft failure was
also examined. RESULTS: 53,997 individuals met the inclusion
criteria. Mean age at time of transplant was 44 years (SD = 15).
Sixty percent were male, 74% were Caucasian, 29% had college
education, and 39% had living donor transplants. At time of
transplant, 5% were on Medicaid and 44% were on Medicare.
CSA, TAC, AZA, MMF and steroids were used by 61%, 34%,
13%, 72% and 97% of RTRs, respectively. About 5.5% of RTRs
were reported as non-adherent and 3% had graft failure within
36 months post-transplant. Non-adherence risk increased with
time and decreased with age (p < 0.001). RTRs who were male,
non-Caucasian, not on Medicare, or used MMF or TAC had
higher risk for non-adherence, with odds ratios (OR) of 1.4, 2.0,
1.6, 1.1, and 1.3 respectively (p < 0.05), while RTRs who used
CSA, steroids or AZA had lower risk (OR = 0.8, 0.5 and 0.7
respectively, p < 0.001). Non-adherent RTRs had higher risk for
graft failure (OR = 5.2, p < 0.001). CONCLUSION: Interven-
tions aimed at improving adherence should target younger RTRs,
male RTRs, non-Caucasian RTRs, and those not on Medicare to
reduce risk of graft failure.
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OBJECTIVES: Haemoglobin cycling is common in haemodialy-
sis patients receiving erythropoiesis-stimulating agents (ESAs). It
is uncertain whether different ESAs are associated with greater
ﬂuctuations in haemoglobin. The purpose of this study was to
compare the within-patient variability in haemoglobin levels in
haemodialysis patients receiving intravenous epoetin alfa or
intravenous darbepoetin alfa. METHODS: Data on haemodial-
ysis patients were extracted from the Renal Anaemia Manage-
ment (RAM) database from 2003 to 2004. The variance in
haemoglobin was calculated for each patient with more than one
haemoglobin observation (n = 4751). A mixed-effects analysis of
variance model was ﬁtted to the within-patient variances and
weighting was based on the number of observations minus 1 for
each patient. The model allowed the treatment comparisons to
be undertaken after taking into account the situations where
patients have data on both products and can hence act as their
own control. RESULTS: The mean within-patient variance in
haemoglobin levels for patients receiving darbepoetin alfa was
23% (95% CI: 16% to 29%) greater than that for patients
receiving epoetin alfa (p < 0.0001). The mean haemoglobin level
for patients receiving darbepoetin alfa was 11.33 g/dL (95% CI:
11.27, 11.38) compared with 11.41 g/dL (95% CI: 11.38, 11.45)
for patients receiving epoetin alfa (p = 0.008). CONCLUSION:
There was greater within-patient ﬂuctuation in haemoglobin
levels in patients receiving darbepoetin alfa compared with
epoetin alfa. The implications of haemoglobin ﬂuctuations on
patient outcomes and resource use require further study.
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OBJECTIVES: To compare the within-patient variability in
haemoglobin levels in pre-dialysis or peritoneal dialysis patients
receiving intravenous epoetin alfa or intravenous darbepoetin
alfa. METHODS: Data on pre-dialysis (n = 169) and peritoneal
dialysis (n = 162) patients were extracted from the Renal
Anaemia Management (RAM) database from 2003 to 2004. The
variance in haemoglobin was calculated for each patient with
more than one haemoglobin observation. A mixed-model was
ﬁtted to the within-patient variances and weighting was based
on the number of observations minus 1 for each patient. The
model took into account the situation where patients had data
on both agents and could therefore act as their own control.
RESULTS: The mean within-patient variance in haemoglobin
levels for pre-dialysis patients receiving darbepoetin alfa was
63% (95% CI: 1% to 163%) greater than that for patients
receiving epoetin alfa (p = 0.045). The mean haemoglobin level
for patients receiving darbepoetin alfa was 10.34 g/dL (95% CI:
9.94, 10.80) compared with 11.22 g/dL (95% CI: 10.95, 11.50)
for patients receiving epoetin alfa (p = 0.001). For peritoneal
dialysis patients, those administered darbepoetin alfa had similar
within-patient variability in haemoglobin levels compared to
those receiving epoetin alfa (darbepoetin 10% greater than
epoetin alfa, 95% CI: −28% to 66%, p = 0.7). The mean haemo-
globin level for patients receiving darbepoetin alfa was 11.49
g/dL (95% CI: 11.19, 11.78) compared with 11.16 g/dL (95%
CI: 10.81, 11.50) for patients receiving epoetin alfa (p = 0.14).
CONCLUSION: In spite of the small sample size, there was a
signiﬁcantly greater within-patient ﬂuctuation in haemoglobin
levels in pre-dialysis patients receiving darbepoetin alfa com-
pared with epoetin alfa, while no difference was seen in peri-
toneal dialysis patients. The implications of haemoglobin
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OBJECTIVES: The objective of this study is to estimate the ﬁve-
year impact on costs associated with hospitalization in patients
under renal replacement therapy (RRT) when a shift in treatment
modality from hemodialysis (HD) to peritoneal dialysis (PD) is
assumed. METHODS: An Excel-based budget impact model
(BIM) was developed to assess the impact of a shift in treatment
modality share. Model inputs included dialysis modality shares,
